Market Cap 137.19B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 7.75
Forward PE 7.95
Profit Margin 12.42%
Debt to Equity Ratio 0.71
Volume 28,585,596
Avg Vol 42,341,488
Day's Range N/A - N/A
Shares Out 5.70B
Stochastic %K 45%
Beta 0.35
Analysts Sell
Price Target $29.05

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 9 at 9:22 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day - every day the instant the P3 results are announced. This is why the lowlife liars are paid to beg us to sell and not buy more.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 8:44 PM
A U.S. appeals court upheld a lower court ruling in favor of AstraZeneca in its patent dispute with Pfizer subsidiary Wyeth over blockbuster lung cancer drug Tagrisso, concluding that the two patents asserted by Wyeth are invalid. The Federal Circuit agreed that the patents lacked sufficient written descriptions and would require undue experimentation for a skilled scientist to reproduce the claimed inventions. Wyeth, which Pfizer acquired in 2009, filed the lawsuit in 2021, alleging that Tagrisso infringed patents related to breast cancer drug Nerlynx, marketed by Puma Biotechnology under a licensing agreement with Pfizer. Although a Delaware jury awarded Wyeth $107.5 million in damages in 2024, the trial judge later overturned that verdict, and the appeals court has now affirmed the decision. The ruling removes a significant legal overhang for AstraZeneca, whose Tagrisso generated more than $7.2 billion in global revenue last year. $AZN $PFE
0 · Reply
jack1342
jack1342 Jul. 9 at 7:59 PM
$PFE people Taking profits last 5 minutes
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 9 at 7:51 PM
$PFE I don't want to sound overly optimistic but I think the market may finally be finished having their way with us and might be letting us slowly craw away on our hands and knees
2 · Reply
LiveSquawk
LiveSquawk Jul. 9 at 6:22 PM
$PFE | Reports Pfizer Fails To Overturn Cancer Drug Patent Cancellation
0 · Reply
JBS_84
JBS_84 Jul. 9 at 5:05 PM
$PFE If it holds see you next week around 25 bucks. I say it will.
1 · Reply
fer69
fer69 Jul. 9 at 5:00 PM
$PFE bought back all my covered calls sold when this was around $28 with a gain of 90% … theta indicates not worth holding them … this should higher after ER
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 9 at 4:57 PM
$PFE can’t wait to close red
1 · Reply
Businesspro
Businesspro Jul. 9 at 4:56 PM
$PFE 👀👍 Added more today IMO current support is $23.70-$24 In for a swing
0 · Reply
Latest News on PFE
Pfizer price target lowered to $28 from $30 at JPMorgan

2026-07-08T12:15:37.000Z - 1 day ago

Pfizer price target lowered to $28 from $30 at JPMorgan


Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade

2026-07-07T15:54:25.000Z - 2 days ago

Pfizer (PFE) Stock Bounces Back After an Analyst Downgrade


Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low

Jul 6, 2026, 10:00 AM EDT - 3 days ago

Options Corner: PFE Downgrade, Stock Slides Near 52-Week Low


Pfizer downgraded to Hold from Buy at HSBC

2026-07-06T09:50:29.000Z - 3 days ago

Pfizer downgraded to Hold from Buy at HSBC


Pfizer Declares Third-Quarter 2026 Dividend

Jun 24, 2026, 3:52 PM EDT - 15 days ago

Pfizer Declares Third-Quarter 2026 Dividend


Pfizer dismissed from US states' drug price-fixing lawsuit

Jun 24, 2026, 10:51 AM EDT - 15 days ago

Pfizer dismissed from US states' drug price-fixing lawsuit


Pfizer CFO Dave Denton to step down, leave company in August

Jun 18, 2026, 6:52 AM EDT - 21 days ago

Pfizer CFO Dave Denton to step down, leave company in August


Pfizer Announces Chief Financial Officer Transition

Jun 18, 2026, 6:45 AM EDT - 21 days ago

Pfizer Announces Chief Financial Officer Transition


US FDA approves Pfizer's bleeding disorder drug for children

Jun 8, 2026, 6:49 AM EDT - 4 weeks ago

US FDA approves Pfizer's bleeding disorder drug for children


Pfizer Transcript: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Transcript: Study update


Pfizer Slides: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Slides: Study update


Pfizer Press release: Study update

Jun 6, 2026, 11:00 AM EDT - 4 weeks ago

Pfizer Press release: Study update


Mailbag: A Follow-Up on Pfizer & Other Questions

May 30, 2026, 9:22 AM EDT - 5 weeks ago

Mailbag: A Follow-Up on Pfizer & Other Questions

AGNC LAND NLY PFFA


Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC

May 5, 2026, 4:09 PM EDT - 2 months ago

Pfizer CEO on Drug Pipeline, Trump's Pick to Lead CDC


Pfizer CEO on AI-designed molecule, and race to use new tech

May 5, 2026, 4:02 PM EDT - 2 months ago

Pfizer CEO on AI-designed molecule, and race to use new tech


3 Dividend Stocks for May 2026

May 5, 2026, 11:30 AM EDT - 2 months ago

3 Dividend Stocks for May 2026

SYY WSO


Pfizer Earnings Call Transcript: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings Call Transcript: Q1 2026


Pfizer Earnings release: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Earnings release: Q1 2026


Pfizer Quarterly report: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Quarterly report: Q1 2026


Pfizer Slides: Q1 2026

May 5, 2026, 10:00 AM EDT - 2 months ago

Pfizer Slides: Q1 2026


Pfizer Posts Better-Than-Expected Revenue, Profit

May 5, 2026, 8:35 AM EDT - 2 months ago

Pfizer Posts Better-Than-Expected Revenue, Profit


Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending

May 5, 2026, 7:23 AM EDT - 2 months ago

Pfizer Revenue Rises But Profit Falls Amid Boosted R&D Spending


Why selling these 3 dividend stocks could be a mistake

May 5, 2026, 7:05 AM EDT - 2 months ago

Why selling these 3 dividend stocks could be a mistake

EPD UPS


Mountainmannn
Mountainmannn Jul. 9 at 9:23 PM
$ABUS $MRNA has to protect their Cancer delivery LPN line promised in negotiations during settlement for release on virus vaccines.. $PFE fighting to protect their ass and gain access to a new drug line. $JNJ just there messing with everyone's wallets because they can.. hahaha tables served let's eat!!
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jul. 9 at 9:22 PM
$SLS $ABBV this $2.6B manipulated mcap will be worth $40B to big pharma $LLY $ABBV $PFE the instant Gps Phase 3 registrational results are announced. $2.6B /$13.5 per share will be worth $40B / $200 per share all day - every day the instant the P3 results are announced. This is why the lowlife liars are paid to beg us to sell and not buy more.
0 · Reply
topstockalerts
topstockalerts Jul. 9 at 8:44 PM
A U.S. appeals court upheld a lower court ruling in favor of AstraZeneca in its patent dispute with Pfizer subsidiary Wyeth over blockbuster lung cancer drug Tagrisso, concluding that the two patents asserted by Wyeth are invalid. The Federal Circuit agreed that the patents lacked sufficient written descriptions and would require undue experimentation for a skilled scientist to reproduce the claimed inventions. Wyeth, which Pfizer acquired in 2009, filed the lawsuit in 2021, alleging that Tagrisso infringed patents related to breast cancer drug Nerlynx, marketed by Puma Biotechnology under a licensing agreement with Pfizer. Although a Delaware jury awarded Wyeth $107.5 million in damages in 2024, the trial judge later overturned that verdict, and the appeals court has now affirmed the decision. The ruling removes a significant legal overhang for AstraZeneca, whose Tagrisso generated more than $7.2 billion in global revenue last year. $AZN $PFE
0 · Reply
jack1342
jack1342 Jul. 9 at 7:59 PM
$PFE people Taking profits last 5 minutes
0 · Reply
MrPeanutEsquire
MrPeanutEsquire Jul. 9 at 7:51 PM
$PFE I don't want to sound overly optimistic but I think the market may finally be finished having their way with us and might be letting us slowly craw away on our hands and knees
2 · Reply
LiveSquawk
LiveSquawk Jul. 9 at 6:22 PM
$PFE | Reports Pfizer Fails To Overturn Cancer Drug Patent Cancellation
0 · Reply
JBS_84
JBS_84 Jul. 9 at 5:05 PM
$PFE If it holds see you next week around 25 bucks. I say it will.
1 · Reply
fer69
fer69 Jul. 9 at 5:00 PM
$PFE bought back all my covered calls sold when this was around $28 with a gain of 90% … theta indicates not worth holding them … this should higher after ER
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 9 at 4:57 PM
$PFE can’t wait to close red
1 · Reply
Businesspro
Businesspro Jul. 9 at 4:56 PM
$PFE 👀👍 Added more today IMO current support is $23.70-$24 In for a swing
0 · Reply
JBS_84
JBS_84 Jul. 9 at 4:24 PM
$PFE Hope it stays above 24.21. That is the 9 day ema and the 200 hr ema
0 · Reply
ultraviolin
ultraviolin Jul. 9 at 4:20 PM
$CRSP $PFE Will re-enter $CRSP once it drops further
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 4:15 PM
0 · Reply
doubleuptwice
doubleuptwice Jul. 9 at 4:13 PM
$PFE avg 23.95 full ported. It’s time now divergence has been rearing
0 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 4:13 PM
$ELTP $PFE $GME $TSLA $DJT Pfizer and Elite Pharmaceuticals are making headlines as talks of a potential deal or buyout surface. Elite Pharmaceuticals (ELTP) has shown impressive growth in 2026, with a 77% revenue increase and strong operating income gains. Meanwhile, Elite Pharma is actively seeking acquisition or merger opportunities, engaging M&A firms to explore strategic options. With Pfizer’s history of strategic partnerships and acquisitions, a collaboration or buyout could significantly impact the pharmaceutical market. Investors are watching closely as this story develops. TRUMP MAKING IT HAPPEN....... THANK YOU DJT.
0 · Reply
WuTangClam
WuTangClam Jul. 9 at 3:39 PM
$PFE back to 26$ 😊
1 · Reply
ResearchTrends09
ResearchTrends09 Jul. 9 at 3:26 PM
$PFE I will post once again …
0 · Reply
ResearchTrends09
ResearchTrends09 Jul. 9 at 3:25 PM
$PFE don’t ever forget
1 · Reply
taxplanr
taxplanr Jul. 9 at 2:58 PM
Bill Gates C19 plandemic lawsuit update $BNTX $MRNA $PFE https://www.instagram.com/reel/DajflFZBTAE/?igsh=bzVodnYwazhtYTB2
0 · Reply
Makingmillions192
Makingmillions192 Jul. 9 at 2:41 PM
$LEXX The macro landscape is completely aligning. The industry is hitting an efficacy ceiling, safety/tolerability has officially become the top priority for pharma executives, and the competition to control the oral market is heating up just as Lexaria is weeks away from dropping definitive human data. $NVO $VKTX $LLY $PFE
0 · Reply
Micheal_Pothead
Micheal_Pothead Jul. 9 at 2:40 PM
$PFE dog
2 · Reply
BarkingPuppy
BarkingPuppy Jul. 9 at 2:39 PM
$ELTP $JNJ $PFE $GME I think PFE is making a deal.... Roaring kitty knowns something.
0 · Reply